1. INTRODUCTION
SARS-CoV-2 causing COVID-19 has affected millions worldwide till date.
Although initially described for its respiratory symptoms and
complications, new research has highlighted the virus’s wide-ranging
effects, which go well beyond the respiratory system. The cardiovascular
system has drawn much attention because of the various cardiac
manifestations, calling for more research and comprehension
The development of new-onset atrial fibrillation (NOAF) in COVID-19 is
one such cardiac manifestation. Several underlying cardiovascular and
systemic conditions have been linked to atrial fibrillation. However,
the intriguing link between COVID-19 and AF has created a particular
focus in cardiovascular medicine, providing additional information about
the underlying mechanisms, clinical implications, and potential
therapeutic options. Although there are variations in the prevalence of
NOAF in COVID-19 as documented by prior studies, it is clear that it can
affect how the disease manifests clinically.,
The presence of NOAF in COVID-19 raises significant clinical and public
health issues, related to the effect of NOAF in COVID-19 outcomes, such
as mortality, hospitalization rates, and the course of the disease.
Hence, we present a systematic review and meta-analysis to compile and
analyze the current literature on NOAF in COVID-19. By combining data
from various studies, we aim to provide a more comprehensive
understanding of the prevalence, clinical importance, and potential
underlying mechanisms of NOAF in COVID-19.